Late Effects in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation for Nonmalignant Diseases: Proxy- and
Joëll E Bense1, Lotte Haverman2, Erik G J von Asmuth1
1Division of Stem cell Transplantation, Department of Pediatrics, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, Netherlands.
Insights
Long-term outcomes after pediatric hematopoietic stem cell transplantation (HSCT) for nonmalignant diseases are generally good, though children and adolescents may experience more sleep disturbances and lower physical health scores. Supportive care is crucial for enhancing long-term well-being.
Area of Science:
- Pediatric Hematology
- Transplantation Medicine
- Patient-Reported Outcomes Research
Background:
- Pediatric hematopoietic stem cell transplantation (HSCT) for nonmalignant diseases has improved survival rates.
- Long-term patient-reported outcomes (PROs) after pediatric HSCT are not well-documented but are crucial for care.
- Understanding PROs informs shared decision-making, counseling, and quality of care.
Purpose of the Study:
- To determine long-term PROs in pediatric allogeneic HSCT recipients for nonmalignant diseases.
- To compare these PROs with Dutch general population reference data.
Main Methods:
- Single-center cohort study of 119 patients (70% response rate) who underwent HSCT at least 2 years prior.
- PROs assessed using PedsQL 4.0 and PROMIS item banks (self- or proxy-reported).
- Comparison of mean scores with age- and sex-matched Dutch reference data.
Main Results:
- Adolescents (13-17 years) reported significantly lower PedsQL scores for Total, Physical Health, and School Functioning.
- Children (8-18 years) reported significantly more Sleep Disturbance.
- Adults (19-30 years) reported better PROMIS Fatigue, Pain Interference, Depressive Symptoms, and Sleep Disturbance scores compared to reference data.
Conclusions:
- Very long-term PROs after pediatric HSCT for nonmalignant diseases are comparable or better than the general population.
- Children and adolescents appear most affected, highlighting the need for targeted supportive care.
- Interventions should focus on improving quality of life and long-term well-being in pediatric HSCT survivors.
Abstract:
Survival rates in pediatric hematopoietic stem cell transplantation (HSCT) for nonmalignant diseases have improved due to advances in conditioning regimens, donor selection, and prophylaxis and treatment of infections and graft-versus-host disease. Insight into the long-term patient-reported outcomes (PROs) after pediatric HSCT for nonmalignant disease is lacking but essential for optimal shared decision making, counseling, and quality of care. The purpose of this research was to determine long-term patient-reported outcomes in allogeneic pediatric HSCT for nonmalignant diseases and to compare these results with Dutch reference data. This single-center cohort study evaluated PROs (PedsQL 4.0, PROMIS item banks), self- or proxy-reported, among patients at ≥2 years after pediatric allogeneic HSCT for nonmalignant disease. Mean scores were compared with those of the Dutch general population. Of 171 eligible patients, 119 participated, for a 70% response rate. The median patient age was 15.8 years (range, 2 to 49 years), and the median duration of follow-up was 8.7 years (range, 2 to 34 years). Indications for HSCT included inborn errors of immunity (n = 41), hemoglobinopathies (n = 37), and bone marrow failure (n = 41). Compared with reference data, significantly lower scores were found in adolescents (age 13 to 17 years) on the Total, Physical Health, and School Functioning PedsQL subscales. Significantly more Sleep Disturbance was reported in children (age 8 to 18 years). On the other hand, significantly better scores were seen on PROMIS Fatigue (age 5 to 7 years) and Pain Interference (age 8 to 18 years) and, in adults (age 19 to 30 years), on Depressive Symptoms and Sleep Disturbance. This study showed better or comparable very long-term PROs in patients after pediatric HSCT for nonmalignant diseases compared with the reference population. Children and adolescents seem to be the most affected, indicating the need for supportive care to prevent impaired quality of life and, more importantly, to amplify their long-term well-being.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Regulation of Hematopoietic Stem Cells
Cell-mediated Immune Responses


